Cara Therapeutics Inc. (NASDAQ:CARA) traded down 1% during trading on Monday . The stock traded as low as $5.01 and last traded at $5.13, with a volume of 210,652 shares changing hands. The stock had previously closed at $5.18.

Several equities research analysts have recently commented on the stock. Needham & Company LLC restated a “buy” rating on shares of Cara Therapeutics in a report on Thursday, April 21st. Cantor Fitzgerald restated a “buy” rating on shares of Cara Therapeutics in a report on Wednesday, April 20th. Piper Jaffray Cos. restated an “overweight” rating and issued a $23.00 price target on shares of Cara Therapeutics in a report on Saturday, April 23rd. Canaccord Genuity restated a “buy” rating and issued a $30.00 price target on shares of Cara Therapeutics in a report on Friday, May 6th. Finally, Zacks Investment Research lowered shares of Cara Therapeutics from a “buy” rating to a “hold” rating in a report on Monday. One analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. Cara Therapeutics presently has an average rating of “Buy” and a consensus target price of $21.21.

The stock’s market cap is $139.41 million. The stock has a 50-day moving average price of $5.52 and a 200 day moving average price of $7.51.

Cara Therapeutics (NASDAQ:CARA) last announced its earnings results on Thursday, May 5th. The biopharmaceutical company reported ($0.39) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.40) by $0.01. The company had revenue of $0.01 million for the quarter, compared to analysts’ expectations of $0.03 million. During the same period last year, the business earned ($0.21) EPS. The company’s quarterly revenue was down 98.6% compared to the same quarter last year. On average, analysts forecast that Cara Therapeutics Inc. will post ($1.72) earnings per share for the current year.

In other Cara Therapeutics news, VP Frederique Ph.D. Menzaghi sold 6,000 shares of the stock in a transaction dated Wednesday, April 20th. The shares were sold at an average price of $9.00, for a total transaction of $54,000.00. Following the completion of the transaction, the vice president now owns 123,000 shares of the company’s stock, valued at $1,107,000. The sale was disclosed in a legal filing with the SEC, which is available at this link.

Several hedge funds have modified their holdings of CARA. EAM Investors LLC boosted its stake in shares of Cara Therapeutics by 97.3% in the fourth quarter. EAM Investors LLC now owns 109,599 shares of the biopharmaceutical company’s stock valued at $1,848,000 after buying an additional 54,046 shares in the last quarter. GSA Capital Partners LLP boosted its stake in shares of Cara Therapeutics by 29.5% in the fourth quarter. GSA Capital Partners LLP now owns 91,073 shares of the biopharmaceutical company’s stock valued at $1,535,000 after buying an additional 20,754 shares in the last quarter. Finally, Jennison Associates LLC boosted its stake in shares of Cara Therapeutics by 0.3% in the fourth quarter. Jennison Associates LLC now owns 656,467 shares of the biopharmaceutical company’s stock valued at $11,068,000 after buying an additional 2,009 shares in the last quarter.

Cara Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing chemical entities designed to alleviate pain and pruritus by focusing on kappa opioid receptors. The Company is engaged in developing product candidates that focus on the body’s peripheral nervous system.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.